Somerset therapeutics endo. and Par Formulations Private Limited, have termin...
Somerset therapeutics endo. and Par Formulations Private Limited, have terminated their respective agreements to acquire Somerset Therapeutics, LLC, a New Jersey based specialty pharmaceutical company, and the business of its India-based affiliate Wintac Limited, which o 4 days ago · Endo International's Investments and acquisitions Endo International has made 1 investments in companies including Cecelia Health. marketplace Feb 27, 2019 · DUBLIN, Feb. S. and the Wintac business will become part of Par Formulations Private Limited. Breaking news and real-time stock market updates from Seeking Alpha. We see significant Feb 27, 2019 · DUBLIN, Feb. marketplace, and the business of… Feb 27, 2019 · DUBLIN, Feb. Check out the latest investing news and financial headlines. and Par Formulations Private Apr 26, 2018 · Endo to Acquire Somerset Therapeutics and Business of Affiliate Wintac Limited DUBLIN, April 26, 2018 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that it has reached definitive agreements to acquire Somerset Therapeutics, LLC, a New Jersey based specialty pharmaceutical company that develops and markets sterile injectable and ophthalmic drugs for the U. 27, 2019 /CNW/ -- Endo International plc (NASDAQ: ENDP) today announced that its subsidiaries, Endo Ventures Limited, Par Pharmaceutical, Inc. Somerset is a sterile pharmaceutical company that manufactures and markets injectable and ophthalmic drugs for the US marketplace. “Additionally, Wintac’s strong sterile R&D and high-quality manufacturing capabilities have contributed greatly to Somerset Therapeutics’ steady revenue growth. 27, 2019 / PRNewswire / -- Endo International plc (NASDAQ: ENDP) today announced that its subsidiaries, Endo Ventures Limited, Par Pharmaceutical, Inc. Somerset Therapeutics, LLC’s primary competitors include Spark Therapeutics, Moderna, Intellia Therapeutics and 20 more. We believe Somerset Therapeutics is an ideal strategic fit for Endo as it expands our portfolio of sterile injectable and ophthalmic products, said Paul Campanelli, President and CEO of Endo. Endo International has also acquired 15 companies including BioSpecifics Technologies and Somerset Therapeutics. Feb 28, 2019 · The Dublin-based Endo and its Par sterile injectables subsidiaries Wednesday said a $190 million agreement to buy sterile injectables company Somerset Therapeutics had been terminated without Apr 26, 2018 · "We believe Somerset Therapeutics is an ideal strategic fit for Endo as it expands our portfolio of sterile injectable and ophthalmic products," said Paul Campanelli, President and CEO of Apr 26, 2018 · We are excited to become a part of Endo and Par, a company we have successfully collaborated with in the past. Apr 26, 2018 · Endo International plc (NASDAQ: ENDP) today announced that it has reached definitive agreements to acquire Somerset Therapeutics, LLC, a New Jersey based specialty pharmaceutical company that Feb 28, 2019 · Endo International plc announced that its subsidiaries, Endo Ventures Limited, Par Pharmaceutical, Inc. 27, 2019 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that its subsidiaries, Endo Ventures Limited, Par Pharmaceutical, Inc. Feb 27, 2019 · This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and any applicable Canadian securities legislation relating to Endo's acquisition of Somerset Therapeutics and Wintac's business. Apr 26, 2018 · DUBLIN, April 26, 2018 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that it has reached definitive agreements to acquire Somerset Therapeutics, LLC, a New Jersey based Apr 26, 2018 · Endo International plc (NASDAQ: ENDP) today announced that it has reached definitive agreements to acquire Somerset Therapeutics, LLC, a New Jersey based specialty pharmaceutical company that develops and markets sterile injectable and ophthalmic drugs for the U. and Par Formulations Private Limited Apr 26, 2018 · DUBLIN, April 26, 2018 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that it has reached definitive agreements to acquire Somerset Therapeutics, LLC, a New Jersey based . and Par Formulations Private “We believe Somerset Therapeutics is an ideal strategic fit for Endo as it expands our portfolio of sterile injectable and ophthalmic products,” said Paul Campanelli, President and CEO of Endo. We see significant opportunities to leverage Feb 27, 2019 · DUBLIN, Feb. Additionally, Wintac s strong sterile R&D and high-quality manufacturing capabilities have contributed greatly to Somerset Therapeutics steady revenue growth. " Upon closing, Somerset Therapeutics will become a wholly-owned subsidiary of Par Pharmaceutical, Inc. Strategic Acquisition Somerset Therapeutics was acquired by Endo International PLC in 2018 for $190 million, indicating strong backing and potential for integrated distribution channels within the pharmaceutical industry. and Par Formulations Private Limited, have terminated their respective agreements to acquire Somerset Therapeutics, LLC, a New Jersey based specialty pharmaceutical company, and the business of its India -based affiliate Wintac Somerset Therapeutics, LLC’s Profile, Revenue and Employees. qfmysfkzlrhwvcaqewwfcxwklzjegnfloqkdruzpnmx